Overcoming the Blood–Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma by Tsung-I Hsu (3401975)

“…Although TMZ is capable of penetrating the blood–brain barrier (BBB), our research addresses the need for targeted therapy to circumvent resistance mechanisms and reduce off-target effects. …”

FIGURE 3 from Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance by Debarshi Banerjee (17620899)

Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF by Ian R. Watson (11911913)

Table S1. Immunosuppressive Pathways Decreased Following miR-200c Restoration from Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a P... by Thomas J. Rogers (8041841)

Data_Sheet_1_Decreased Antibiotic Susceptibility in Pseudomonas aeruginosa Surviving UV Irradition.docx by Hai-bei Li (8180724)

“…Mechanistically, UV exposure causes oxidative stress in P. aeruginosa and consequently induces dysregulation of genes contributed to the related antibiotic resistance genes. …”

Gut dysbacteriosis attenuates resistance to <i>Mycobacterium bovis</i> infection by decreasing cyclooxygenase 2 to inhibit endoplasmic reticulum stress by Haoran Wang (272166)

Cabozantinib significantly decreases tumor volume and prolongs survival in SCNPC PDX models. by Mark P. Labrecque (10011469)

Supplementary Fig. S8 from Proteasome Inhibition Overcomes ALK-TKI Resistance in <i>ALK</i>-Rearranged/<i>TP53</i>-Mutant NSCLC via Noxa Expression by Azusa Tanimoto (14936243)

Supplementary Figure 1 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors by Sandra Ortiz-Cuaran (320342)

Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors by Sandra Ortiz-Cuaran (320342)

FIGURE 2 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects by Alexandria P. Eiken (18597722)

Supplemental Figure S1 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model by Eva Tonsing-Carter (7039142)

Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 5 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)